Skip to main content
Michael Haggenmueller
100

Prof. Dr. Michael Sattler

Department Head, Molecular Targets & Therapeutics Center

Director, Institute of Structural Biology and Bavarian NMR Center

"We combine integrative structural biology to elucidate molecular mechanisms of biological pathways, highlighting the essential roles of dynamics and transient regulatory interations to enable innovative structure-based drug discovery."

Prof. Dr. Michael Sattler

Department Head, Molecular Targets & Therapeutics Center

Director, Institute of Structural Biology and Bavarian NMR Center

"We combine integrative structural biology to elucidate molecular mechanisms of biological pathways, highlighting the essential roles of dynamics and transient regulatory interations to enable innovative structure-based drug discovery."

Career

Michael Sattler studied chemistry and developed novel nuclear magnetic resonance (NMR)-spectroscopy methods to study biological macromolecules during his doctoral studies at the University of Frankfurt. As a postdoc with Steve Fesik (Abbott labs) he employed advanced NMR methods to solve landmark structures of Bcl family proteins involved in the regulation of apoptosis signaling. With his own research group established at the European Molecular Biology Laboratory (EMBL), Heidelberg, in 1997, he pioneered structural biology of proteins and RNAs that play critical roles in eukaryotic gene regulation, such as alternative pre-mRNA splicing in collaboration with Juan Valcarcel (now at CRG Barcelona) and mechanisms of non-coding RNAs.

Since moving to Helmholtz Munich and TUM in 2007 his lab studies the structural mechanisms and functional roles of essential steps in the early assembly and biogenesis of the spliceosome and its regulation. These studies revealed unique insight into the recognition of the key RNA motifs at the 3’ splice site of human introns by essential splicing factors, SF1 (Science 2001) and U2AF (Nature 2011), highlighting how dynamic recognition enables graduated regulation. His lab unraveled the structural basis of the recognition of arginine methylation marks by the Survival of Motor Neurons (SMN) Tudor domain, linked to spinal muscular atrophy disease.

Michael developed efficient protocols for integrative structural biology in solution by combining NMR, small angle scattering, crystallography and cryo-EM and helped to establish high-end infrastructures for structural biology (1.2 GHz NMR, www.bnmrz.org, and cryo-EM).

Current work focusses on structure and dynamics of (long) non-coding RNAs implicated in human disease, their regulation by posttranscriptional modifications (i.e. m6A) and RNA binding proteins, as well as structural dynamics in biological and disease-linked cellular pathways involving the molecular chaperone Hsp90 and peroxisome biogenesis pathways.

Insight into structural mechanisms of disease pathways provides the basis for innovative structure-based drug discovery to develop novel therapeutic approaches for human disease, including cancer, genetic disorders, and (neglected) infectious diseases.

 

Skills and Expertise

Integrative structural biology biomolecular NMR-spectroscopy structure-based drug discovery

RNA-based gene regulationalternative splicingmiRNA processingcellular signalingperoxisome biogenesismolecular chaperones Hsp90

Facts and Figures

2007

Director, Bavarian NMR Center

2007

Professor (W3) Biomolecular NMR, Chemistry Department, Technical University of Munich

2007

Director, Institute of Structural Biology, Helmholtz Munich

2007

School of Natural Sciences, Technical University of Munich

1997

Group Leader Structural Biology, EMBL Heidelberg

1995

Dr. phil. nat. Chemistry, Dr. phil. nat. Universität Frankfurt, Germany

1995

Postdoc Abbott Labs, Chicago

Honors and Awards

suppa - stock.adobe.com
  • 2020
    Erwin-Schrödinger Prize/Stifterverband Science Award

  • 2017
    Elected Member of the Leopoldina, German National Academy of Sciences

  • 2017
    Elected Member ISMAR Council (International Society of Magnetic Resonance)

  • 2014
    FEBS National Lecturer Spanish Biochemical Society (SEBB), Granada

  • 2012
    Elected EMBO Member

  • 2011-2012
    Visiting Professorship for Senior International Scientists, Tianjin, China

  • 2005
    Professor Invité, Ecole Normale Superieur, Paris, France

  • 2005
    Jean-Francois Lefevre Lecturer in Biophysics, Strasbourg, France

more

Private thought

"Basic research and development of new methods are the foundation for innovative discoveries and their translation for human health."

"Basic research and development of new methods are the foundation for innovative discoveries and their translation for human health."

Patents

2020: EPA No. 20214108.1 Inhibition of virus protease

Discovery of a clinically approved repurposing drug as potent inhibitor of SARS-CoV-2 replication

2016:  PCT/EP2016/080316 CPAP-Tubulin Module

A novel concept for cancer therapy by inhibition of the CPAP-Tubulin interation

2016: WO2016038045 Pyrazolopyridine derivatives and their use in therapy

A new concept for treating trypanosome diseases, such as Chagas, by inhibiting a protein-protein interaction that is essential for protein import into glycosomes

Twitter feed

Research networks

2022

Co-organizer EMBO Practical Course “NMR spectroscopy of biological macromolecules, with S Grzesiek Biozentrum Basel, M. Nilges, Pasteur, M. Ringkoping-Jensen (IBS Grenoble)-  biannually since 1999 (25 students and postdocs)

 

 

2019

Co-organizer International conference New Frontiers in Structure-based Drug Discovery¸Florence, Italy, with Christian Ottmann (supported by ITNs AEGIS and TASPPI)

 

 

 

2018 - 2022

Co-coordination: EU Horizon 2020 ITN RNAct     Enabling proteins with RNA recognition motifs for synthetic biology and bio-analytics, with Wim Vranken, VUB Brussels http://rnact.eu/

 

 

 

 

 

 

2018

International Helmholtz Drug Discovery Conference - HDDC 2018, Munich

 

 

 

 

 

 

2017

Co-organizer Keystone Symposium: Frontiers of NMR in Life Sciences; co-organizer with K. Wüthrich; S.W. Fesik; 170 participants

 

 

 

 

 

 

 

2016 - 2020

Coordinator: EU Horizon 2020 ITN AEGIS - Accelerated early stage drug discovery http://www.aegis-itn.eu/

2022

Co-organizer EMBO Practical Course “NMR spectroscopy of biological macromolecules, with S Grzesiek Biozentrum Basel, M. Nilges, Pasteur, M. Ringkoping-Jensen (IBS Grenoble)-  biannually since 1999 (25 students and postdocs)

 

 

2019

Co-organizer International conference New Frontiers in Structure-based Drug Discovery¸Florence, Italy, with Christian Ottmann (supported by ITNs AEGIS and TASPPI)

 

 

 

2018 - 2022

Co-coordination: EU Horizon 2020 ITN RNAct     Enabling proteins with RNA recognition motifs for synthetic biology and bio-analytics, with Wim Vranken, VUB Brussels http://rnact.eu/

 

 

 

 

 

 

2018

International Helmholtz Drug Discovery Conference - HDDC 2018, Munich

 

 

 

 

 

 

2017

Co-organizer Keystone Symposium: Frontiers of NMR in Life Sciences; co-organizer with K. Wüthrich; S.W. Fesik; 170 participants

 

 

 

 

 

 

 

2016 - 2020

Coordinator: EU Horizon 2020 ITN AEGIS - Accelerated early stage drug discovery http://www.aegis-itn.eu/